Ganciclovir
- Generic Name
- Ganciclovir
- Brand Names
- Cytovene, Zirgan
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N5O4
- CAS Number
- 82410-32-0
- Unique Ingredient Identifier
- P9G3CKZ4P5
- Background
An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
- Indication
For induction and maintenance in the treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). Also used in the treatment of severe cytomegalovirus (CMV) disease, including CMV pneumonia, CMV gastrointestinal disease, and disseminated CMV infections, in immunocompromised patients.
- Associated Conditions
- CMV colitis, Cytomegalovirus (CMV) Infections, Cytomegalovirus Retinitis, Cytomegalovirus gastroesophagitis, Varicella-zoster Progressive outer retinal necrosis, Acute Herpetic keratitis, Cytomegalovirus neurological disease, Varicella-zoster virus acute retinal necrosis
Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy
- Conditions
- Acute Renal FailureCytomegalovirus InfectionsMulti Organ Failure
- First Posted Date
- 2005-12-12
- Last Posted Date
- 2007-06-28
- Lead Sponsor
- University of Oslo School of Pharmacy
- Target Recruit Count
- 6
- Registration Number
- NCT00264368
- Locations
- 🇳🇴
Rikshospitalet, Section of Nephrology, Oslo, Norway
Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant
- Conditions
- Cytomegalovirus Infections
- Interventions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2013-07-23
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 39
- Registration Number
- NCT00241345
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT00217503
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation
- Conditions
- Kidney TransplantRenal TransplantationKidney TransplantationKidney DiseasesRenal Transplant
- Interventions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2016-11-29
- Target Recruit Count
- 130
- Registration Number
- NCT00141037
- Locations
- 🇺🇸
UCLA - Department of Pediatrics, Division of Nephrology, Los Angeles, California, United States
🇺🇸Children's Hospital Boston - Division of Nephrology, Boston, Massachusetts, United States
🇺🇸Children's Hospital of New Orleans-Department of Pediatric Nephrology, New Orleans, Louisiana, United States
Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma
- Conditions
- Melanoma (Skin)
- First Posted Date
- 2004-08-09
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- National Human Genome Research Institute (NHGRI)
- Registration Number
- NCT00005057
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸Clinical Genetherapy Branch, Bethesda, Maryland, United States
🇺🇸Metabolism Branch, Bethesda, Maryland, United States
Gene Therapy in Treating Patients With Primary Brain Tumors
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2004-07-29
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Registration Number
- NCT00002824
- Locations
- 🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
Vaccine Therapy and Ganciclovir in Treating Patients With Mesothelioma
- Conditions
- Malignant Mesothelioma
- Locations
- 🇺🇸
Louisiana State University School of Medicine, New Orleans, Louisiana, United States
Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma
- Conditions
- Neuroblastoma
- First Posted Date
- 2003-12-31
- Last Posted Date
- 2010-09-21
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00006480
- Locations
- 🇺🇸
Cancer Center and Beckman Research Institute, City of Hope, Duarte, California, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
- Conditions
- Fallopian Tube CancerPrimary Peritoneal Cavity CancerOvarian Cancer
- First Posted Date
- 2003-05-05
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- John Stoddard Cancer Center at Iowa Methodist Medical Center
- Registration Number
- NCT00005025
- Locations
- 🇺🇸
Human Gene Therapy Research Institute, Des Moines, Iowa, United States
Zidovudine Plus Interleukin-2 and Ganciclovir in Treating Patients With AIDS-Related Primary Central Nervous System Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-02-03
- Lead Sponsor
- AIDS Malignancy Consortium
- Registration Number
- NCT00006264
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
🇺🇸Sylvester Cancer Center, University of Miami, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.